Company news

Seres Therapeutics, Inc. news in 2025

Seres Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

November 24, 2025

Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

November 5, 2025

Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025

October 30, 2025

Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155

October 29, 2025

Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant

October 14, 2025

Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway

September 23, 2025

Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference

August 27, 2025

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 6, 2025

Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025

July 22, 2025

Seres Therapeutics Announces Leadership Transition

July 22, 2025

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting

May 27, 2025

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

May 7, 2025

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

April 29, 2025

Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025

April 23, 2025

Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

March 13, 2025

Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025

March 4, 2025

Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach

March 3, 2025

Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale

January 15, 2025

Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

January 8, 2025

Calls in 2025

Decks in 2025